Operator: Good afternoon, and welcome to the Cadence Pharmaceuticals Fourth Quarter and Full Year 2011 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Bill LaRue, Senior Vice President and Chief Financial Officer; Jim Breitmeyer, Executive Vice President and Chief Medical Officer and Scott Byrd, Senior Vice President and Chief Commercial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the Company, we will open the conference up for questions and answers after the presentation of the management.
Our first speaker is Bill LaRue. Please go ahead, sir.
William R. LaRue - SVP, CFO, Treasurer and Assistant Secretary: Good afternoon, everyone. Before we begin, I'd like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding financial estimates and projections, expectations regarding sales, formulary approvals, revenue growth, and the market opportunity for OFIRMEV, our belief that the lots of finished product placed on hold may not be salable at the completion of our investigation into certain quality issues, and that these issues will not impact any other lots of the product, expectations regarding the ability of our contract manufacturers to continue to supply adequate quantities of OFIRMEV to meet market demand, and the sufficiency of our capital resources to fund our operations. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in our business. These risks include our dependence on the successful commercialization of OFIRMEV, which is our only product, and our ability to achieve market acceptance and generate revenues from sales of OFIRMEV, our ability to successfully enforce our marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, potential product liability exposure, our dependence on our contract manufacturers and our ability to ensure an adequate supply of OFIRMEV to meet market demand, our ability to fully comply with the loss and regulatory requirements that apply to our business, the risk that we may not be able to raise sufficient capital when needed or at all, and other risks detailed under Risk Factors and elsewhere in our periodic reports and our other filings made with the Securities and Exchange Commission from time to time.
All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update the information discussed during this call to reflect events or circumstances after this call.
If anyone has not seen our press release issued today, you can access it on our website at www.cadencepharm.com. We also post and maintain the current version of our corporate presentation on the Investor Relations portions of our website under Events and Presentation and then Corporate Overview. Additionally, this conference call is being webcast through our website and will be archived there for future reference. Ted?